{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:36:44Z","timestamp":1771015004378,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016899","name":"Yale New Haven Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ncl.2025.08.009","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:04:34Z","timestamp":1758769474000},"page":"63-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Placebo Effects in the Treatment of Depression\u2014Implications for the Psychedelic Renaissance"],"prefix":"10.1016","volume":"44","author":[{"given":"Mina","family":"Ansari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie I.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie E.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2025.08.009_bib1","series-title":"Major depression","author":"Health","year":"2022"},{"key":"10.1016\/j.ncl.2025.08.009_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.15585\/mmwr.mm7224a1","article-title":"National, State-Level, and county-level prevalence estimates of adults aged \u226518 years self-reporting a lifetime diagnosis of depression \u2014 united States, 2020","volume":"72","author":"Lee","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10128","key":"10.1016\/j.ncl.2025.08.009_bib3","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.009_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.31887\/DCNS.2002.4.1\/ssonawalla","article-title":"Placebo response in depression","volume":"4","author":"Sonawalla","year":"2002","journal-title":"Dialogues Clin Neurosci"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.009_bib5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A model of placebo response in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am J Psychiatr"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.009_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.pupt.2013.01.006","article-title":"Mechanisms of the placebo response","volume":"26","author":"Benedetti","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"issue":"6942","key":"10.1016\/j.ncl.2025.08.009_bib7","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/bmj.308.6942.1499","article-title":"Statistic notes: regression towards the mean","volume":"308","author":"Bland","year":"1994","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.009_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/ebmed-2017-110884","article-title":"Catalogue of bias: observer bias","volume":"23","author":"Mahtani","year":"2018","journal-title":"BMJ Evidence-Based Medicine"},{"key":"10.1016\/j.ncl.2025.08.009_bib9","article-title":"Understanding the Hawthorne effect","volume":"351","author":"Sedgwick","year":"2015","journal-title":"BMJ Br Med J (Clin Res Ed)"},{"issue":"45","key":"10.1016\/j.ncl.2025.08.009_bib10","doi-asserted-by":"crossref","first-page":"10390","DOI":"10.1523\/JNEUROSCI.3458-05.2005","article-title":"Neurobiological mechanisms of the placebo effect","volume":"25","author":"Benedetti","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.ncl.2025.08.009_bib11","article-title":"Placebo stimulates neuroplasticity in depression: implications for clinical practice and research","volume":"14","author":"Seymour","year":"2023","journal-title":"Front Psychiatr"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.009_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000490354","article-title":"Implications of placebo and nocebo effects for clinical practice: expert consensus","volume":"87","author":"Evers","year":"2018","journal-title":"Psychother Psychosom"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.009_bib13","doi-asserted-by":"crossref","first-page":"e2125531","DOI":"10.1001\/jamanetworkopen.2021.25531","article-title":"Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis","volume":"4","author":"Jones","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.009_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level meta-analysis","volume":"303","author":"Fournier","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.009_bib15","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.009_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12888-016-1173-2","article-title":"Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.009_bib17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.009_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00004714-200202000-00007","article-title":"Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database","volume":"22","author":"Khan","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.009_bib19","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/acps.13340","article-title":"Determining maximal achievable effect sizes of antidepressant therapies in placebo-controlled trials","volume":"144","author":"Hieronymus","year":"2021","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.ncl.2025.08.009_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-3-662-44519-8_16","article-title":"The emperor\u2019s new drugs: medication and placebo in the treatment of depression","volume":"225","author":"Kirsch","year":"2014","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.ncl.2025.08.009_bib21","series-title":"Placebo talks: modern perspectives on placebos in society","first-page":"0","article-title":"17Antidepressants and the placebo effect","author":"Kirsch","year":"2015"},{"key":"10.1016\/j.ncl.2025.08.009_bib22","article-title":"Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis","volume":"378","author":"Stone","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ncl.2025.08.009_bib23","first-page":"10","article-title":"Placebo effect in the treatment of depression and anxiety","author":"Kirsch","year":"2019","journal-title":"Front Psychiatr"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.009_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0895-4356(94)00141-C","article-title":"Cost-effectiveness comparisons using \u201creal world\u201d randomized trials: the case of new antidepressant drugs","volume":"48","author":"Simon","year":"1995","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.009_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041778","article-title":"A systematic review of comparative efficacy of treatments and controls for depression","volume":"7","author":"Khan","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.ncl.2025.08.009_bib26","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.009_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/wps.20421","article-title":"Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013","volume":"16","author":"Khan","year":"2017","journal-title":"World Psychiatry"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.009_bib28","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","article-title":"Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies","volume":"3","author":"Furukawa","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ncl.2025.08.009_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jad.2020.03.065","article-title":"Placebo response rates in trials of antidepressant drugs in adults with clinical depression: increasing, decreasing, constant or all of the above?","volume":"271","author":"Parker","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.ncl.2025.08.009_bib30","article-title":"Navacaprant for major depressive disorder fails in late-stage study","author":"Kuntz","year":"2025","journal-title":"Psychiatr Times"},{"key":"10.1016\/j.ncl.2025.08.009_bib31","series-title":"NCT04663321; efficacy and safety of MK-1942 when added to stable antidepressant therapy in participants with treatment-resistant depression (TRD) (MK-1942-006)","author":"Medicine","year":"2024"},{"key":"10.1016\/j.ncl.2025.08.009_bib32","series-title":"American Society of clinical psychopharmacology","article-title":"Efficacy and safety of a single administration of the N-methyl-D-aspartate subunit 2B-Selective negative allosteric modulator, BI 1569912, in people living with major depressive disorder: a phase Ib randomized controlled trial","author":"McIntyre RS","year":"2025"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.009_bib33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","article-title":"Preparing for the bursting of the psychedelic hype bubble","volume":"79","author":"Yaden","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.009_bib34","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s44220-023-00141-w","article-title":"Placebo\u2019s role in the rapid antidepressant effect","volume":"1","author":"Sanacora","year":"2023","journal-title":"Nature Mental Health"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.009_bib35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.009_bib36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","article-title":"The neural basis of psychedelic action","volume":"25","author":"Kwan","year":"2022","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.ncl.2025.08.009_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.ncl.2025.08.009_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1346697","article-title":"Hype or hope? High placebo response in major depression treatment with ketamine and esketamine: a systematic review and meta-analysis","volume":"15","author":"Matsingos","year":"2024","journal-title":"Front Psychiatr"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.009_bib39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/psymed.2023.0028","article-title":"A systematic review of study design and placebo controls in psychedelic research","volume":"2","author":"Wen","year":"2023","journal-title":"Psychedelic Medicine"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.009_bib40","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ije\/dyu115","article-title":"Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies","volume":"43","author":"Hrobjartsson","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.009_bib41","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41386-019-0317-8","article-title":"Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant","volume":"44","author":"Wilkinson","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.009_bib42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2023.1412","article-title":"The intricate interaction between expectations and therapeutic outcomes of psychedelic agents","volume":"80","author":"Colloca","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.009_bib43","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","article-title":"LSD enhances suggestibility in healthy volunteers","volume":"232","author":"Carhart-Harris","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"10.1016\/j.ncl.2025.08.009_bib44","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0269881116677852","article-title":"Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology","volume":"30","author":"Hartogsohn","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.009_bib45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol Rev"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.009_bib46","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamapsychiatry.2022.2996","article-title":"Evaluation of early ketamine effects on belief-updating biases in patients with treatment-resistant depression","volume":"79","author":"Bottemanne","year":"2022","journal-title":"JAMA Psychiatry"},{"issue":"16","key":"10.1016\/j.ncl.2025.08.009_bib47","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.009_bib48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ncl.2025.08.009_bib49","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ncl.2025.08.009_bib50","series-title":"GH research announces primary endpoint met in phase 2b trial with GH001 in TRD demonstrating -15.5 point placebo-adjusted MADRS reduction","author":"Research","year":"2025"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.009_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.24119","article-title":"Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis","volume":"8","author":"Hieronymus","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"14","key":"10.1016\/j.ncl.2025.08.009_bib51","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depressionvariable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.009_bib52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/HRP.0b013e3182a75cc7","article-title":"Massachusetts general hospital SAFER criteria for clinical trials and research","volume":"21","author":"Desseilles","year":"2013","journal-title":"Harv Rev Psychiatr"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.009_bib53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/JCP.0000000000000669","article-title":"Guarding the gate: remote structured assessments to enhance enrollment precision in depression trials","volume":"37","author":"Freeman","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.009_bib54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0b013e3181d20912","article-title":"Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response","volume":"30","author":"Kobak","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.009_bib55","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jpsychires.2013.02.016","article-title":"A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of major depressive disorder","volume":"47","author":"Targum","year":"2013","journal-title":"J Psychiatr Res"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.009_bib56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother Psychosom"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.009_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41386-023-01600-9","article-title":"How should we design future mechanistic and\/or efficacy clinical trials?","volume":"49","author":"Fava","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.009_bib58","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41386-020-00911-5","article-title":"Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders","volume":"46","author":"Cohen","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.ncl.2025.08.009_bib59","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/17512433.2023.2279736","article-title":"Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis","volume":"16","author":"Muthukumaraswamy","year":"2023","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.ncl.2025.08.009_bib60","unstructured":"Food and Drug Administration, F. D. A. Psychedelic Drugs:Considerations for Clinical Investigations Guidance for Industry. Docket Number FDA-2023-D-1987 fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investiations 2023 (accessed July, 18)."},{"issue":"6","key":"10.1016\/j.ncl.2025.08.009_bib61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamapsychiatry.2025.0442","article-title":"Issues in clinical trial design-lessons from the FDA\u2019s rejection of MDMA","volume":"82","author":"Wilkinson","year":"2025","journal-title":"JAMA Psychiatry"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T21:07:48Z","timestamp":1766092068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0733861925000593"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.08.009","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo Effects in the Treatment of Depression\u2014Implications for the Psychedelic Renaissance","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}